

# What have we learned from SHIVA?

Nature Reviews Clinical Oncology

13, 719-720

DOI: [10.1038/nrclinonc.2016.164](https://doi.org/10.1038/nrclinonc.2016.164)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 317-323.	12.5	60
2	Precision oncology based on omics data: The NCT Heidelberg experience. <i>International Journal of Cancer</i> , 2017, 141, 877-886.	2.3	133
3	Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. <i>Cancer Research</i> , 2017, 77, 6313-6320.	0.4	22
4	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017, 87, 122-130.	1.3	120
5	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017, 2017, 1-18.	1.5	107
6	A robust targeted sequencing approach for low input and variable quality DNA from clinical samples. <i>Npj Genomic Medicine</i> , 2018, 3, 2.	1.7	20
7	Precision medicine strategies in oncology: mixed approaches to matched therapies. <i>Future Oncology</i> , 2018, 14, 105-109.	1.1	1
8	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. <i>Nature Reviews Urology</i> , 2018, 15, 92-111.	1.9	139
9	Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for <i>NTRK</i> -Targeted Therapeutics. <i>JCO Precision Oncology</i> , 2018, 2018, 1-20.	1.5	201
10	Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	0
11	Community-driven development of a modified progression-free survival ratio for precision oncology. <i>ESMO Open</i> , 2019, 4, e000583.	2.0	22
12	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 130.	6.9	64
13	3. Clinical Research in Precision Medicine Oncology. , 2019, , 60-80.		0
14	Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. <i>Cancer Biology and Therapy</i> , 2019, 20, 219-226.	1.5	30
15	Precision Medicine Clinical Trials: Successes and Disappointments, Challenges and Opportunities â€“ Lessons Learnt. , 2019, , 593-603.		1
16	Strategies for Testing Intervention Matching Schemes in Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 542-552.	2.3	9
17	Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. <i>Molecular Oncology</i> , 2021, 15, 67-79.	2.1	28
19	Next-Generation Sequencing in Prostate Cancer. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 18-23.	0.1	0

#	ARTICLE	IF	CITATIONS
20	Variable Mutation Expression in Human Cancers: A "Hide-and-Seek" Mechanism Linked to Differential MHC-I Presentation Dynamics. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1219-1226.	1.9	0
21	Clinical trial design in the era of precision medicine. <i>Genome Medicine</i> , 2022, 14, .	3.6	68
22	Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?. <i>JCO Precision Oncology</i> , 2023, , .	1.5	0